Stock INMB INMUNE BIO, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus INmune Bio, Inc.

Equities

INMB

US45782T1051

Real-time Estimate Cboe BZX
Other stock markets
 16:50:37 02/05/2024 BST 		5-day change 1st Jan Change
11.24 USD -3.06% Intraday chart for INmune Bio, Inc. +4.98% +1.07%
04-30 INmune Bio, Inc. Provides Update on Two Patients from the Phase 1b Alzheimer's Disease Trial CI
04-29 INmune Bio Inc. Completes First Cohort and Initiates Second Cohort of Phase 1/2 Study of INKmune?? Natural Killer Cell Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer CI

Evolution of the average Target Price on INmune Bio, Inc.

Price target over the last 5 years

History of analyst recommendation changes

03d697672ca461c9.T8fX8g7wWznXkN2_bgf2Er2JxEpCCU-pF4R64irDsOI.DLe-tlmGOU_n05uPLzGjVNvo83txXxDTItVDp16t6IMA9oGRSpQNaOHGnA~d88c41fde9f56791a317bc25e36c5476

Analyst Recommendations on INmune Bio, Inc.

Baird Initiates INmune Bio at Outperform With $16 Price Target MT
INmune Bio Shares Rebound From 52-Week Low, Up 9% DJ
INmune Bio Shares Hit 52-Week Low After FDA Requests More Data on XPro1595 DJ
BTIG Adjusts INmune Bio's Price Target to $14 From $31, Reiterates Buy Rating MT
B. Riley Downgrades INmune Bio to Neutral from Buy on Chemistry Manufacturing and Controls-Related FDA Hold, Lowers Price Target to $7 from $14 MT
B. Riley Lowers INmune Bio's Price Target to $14 from $20, Notes Higher Cost of Capital; Keeps Buy Rating MT
B. Riley Lowers INmune Bio's Price Target to $20 from $32 After Revising Cost Capital Assumptions, Keeps Buy Rating MT
INMUNE BIO : B. Riley Raises INmune Bio's PT to $32 from $26, Notes 'Encouraging' Datasets From 2 Lead Programs; Keeps Buy Rating MT
INMUNE BIO : B. Riley Lowers INmune Bio's PT to $26 from $34 on Revised Costs and Timeline for AD Development, Keeps Buy Rating MT
INMUNE BIO : B. Riley Raises INmune Bio's PT to $34 from $29 Driven by Pipeine Progress, Simplification of Capital Structure; Keeps Buy Rating MT
INMUNE BIO : B. Riley Starts INmune Bio at Buy with $29 PT; Says Breast Cancer, Alzheimer's Programs Represent Potential Upside to Model MT
INMUNE BIO : HC Wainwright Adjusts INmune Bio's Price Target to $15 from $20, Keeps Buy Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
11.6 USD
Average target price
18.5 USD
Spread / Average Target
+59.48%
High Price Target
21 USD
Spread / Highest target
+81.03%
Low Price Target
16 USD
Spread / Lowest Target
+37.93%

Consensus detail

Consensus revision (last 18 months)

Analysts covering INmune Bio, Inc.

Baird
B. Riley
BTIG

Ratings for INmune Bio, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. INMB Stock
  4. Consensus INmune Bio, Inc.